Case Report

T cell/histiocyte rich large B cell lymphoma of ascending colon: a rare entity

Vinita Agrawal¹, Mithlesh Bhargav¹, Supriya Sharma², Vaibhav Raj Gopal³*

1Department of Pathology, SGPGIMS, Lucknow, Uttar Pradesh, India
2Department of Surgical Gastroenterology, SGPGIMS, Lucknow, Uttar Pradesh, India
3Department of General Surgery, KGMU, Lucknow, Uttar Pradesh, India

Received: 15 December 2019
Accepted: 31 January 2020

*Correspondence:
Dr. Vaibhav Raj Gopal,
E-mail: twinlke1@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Colonic T cell/histiocyte rich large B cell lymphoma (THRLBCL) is a very unusual occurrence never described before. A 41-year anaemic male presented with loss of weight and appetite for 7 months and fever with Malena for 1 month. Abdominal examination revealed a 4x6 cm retroperitoneal lump in the right iliac fossa. Radiological investigations (USG and CECT whole abdomen) reported an asymmetrical ill-defined growth in ascending colon and caecum with loco-regional lymphadenopathy. Surgical exploration revealed an ascending colon mass with retroperitoneal lymphadenopathy. Right hemicolectomy with end ileostomy was done and specimen was sent for histopathology which diagnosed it to be a case of THRLBCL of colon. Patient was followed up after 2 weeks and was planned for chemotherapy.

Keywords: Colonic epithelial malignancy, Diffuse large B-cell lymphoma, Lenalidomide, Nodular lymphocyte predominant Hodgkin lymphoma, T cell/histiocyte rich large B cell

INTRODUCTION

T cell/histiocyte rich large B cell lymphoma (THRLBCL) is classified as a subset of the DLBCL according to the revised WHO classification of hemato-lymphoid neoplasms 2017. It is a high grade, aggressive non-Hodgkin lymphoma, affecting mainly middle-aged men.¹ ² Morphologically it mimics NLP/HL and classic Hodgkin lymphoma (cHL). It mainly has predilection for lymph nodes, spleen and liver but rare extra-nodal sites include thyroid, small intestine and thymus.³ ⁵ THRLBCL of colon is an extremely unusual presentation and very rare.

CASE REPORT

A 41 year male farmer, presented with progressive weakness, loss of weight and appetite for 7 months and low-grade fever and Malena for 1 month. No history of vomiting, abdominal pain, and constipation. He was a chronic smoker. Family history was insignificant. No history of concurrent medical illnesses and long-term drug intake. On examination he had fair general condition, pallor was present and abdominal examination revealed a 4x6 cm retroperitoneal lump in the right iliac fossa. No generalized lymphadenopathy was present. Per rectal examination was normal.

Investigations

Hemoglobin: 5.4 g%, serum CEA: 2.29 mcg/l

USG whole abdomen: Hypo-echoic mural thickening of distal ileum, ileo-caecal junction and caecum with multiple enlarged lymph nodes.

CECT whole abdomen: 11 cm long, asymmetrical, circumferential heterogeneously enhancing wall thickening in caecum and ascending colon. Multiple
enlarged necrotic peri-pancreatic, periportal and aortocaval lymph nodes were also noted (Figure 1).

**Colonoscopy:** Multiple ulcers with surrounding edema extending from hepatic flexure up to caecum. Intervening mucosa was normal in appearance.

![Figure 1: CECT whole abdomen depicting irregular growth in the ascending colon.](image)

**Differential diagnosis**

Colonic epithelial malignancy, ileocaecal tuberculosis, Crohn’s colitis.

**Treatment**

Patient was planned for elective laparotomy after adequate pre surgical optimization. Surgical exploration revealed an ulceropolyploiferative growth in ascending extending till the hepatic flexure and fixed to a knuckle of second part of duodenum superiorly. Multiple lymph nodes, largest measuring 3 cm identified at the root of mesentery, mesocolon, and retroperitoneum. No omental, peritoneal or serosal nodules seen. Patient underwent palliative (in view of melaena) right hemicolecction with sleeve duodenectomy with end ileostomy, distal stump closure along with duodenal rent repair. The specimen was submitted for histopathology. Hospital course of the patient was uneventful, and he was discharged after 10 days.

**Outcome and follow-up**

On gross examination, grey white ill-defined nodular growth measuring 6.5×4×2.7 cm in ascending colon was identified (Figure 2). Histopathology showed polymorphous population of cells with many dispersed large atypical cells dispersed in a background of lymphocytes, histiocytes, few eosinophils, and plasma cells. The large cells displayed round, lobated, or irregularly folded nuclei and distinct nucleoli and moderate amount of cytoplasm. (Figure 3) Four out of seven peri colonic lymph nodes were also involved. Immunohistochemistry showed large atypical cells positive for vimentin (Figure 4), LCA (Figure 5), CD30, Bcl2 and PAX5 (Figure 6). The background T cells and histiocytes were CD3 (Figure 7) and CD68 (Figure 8) positive.

![Figure 2: Grey white ill-defined nodular growth which measures 6.5×4×2.7 cm in ascending colon.](image)

![Figure 3: Section from colonic growth showing atypical cells with round to irregular folded nuclei, distant nucleoli and moderate cytoplasm. Few bizarre cells along with polymorphous population also noted (20X).](image)

![Figure 4: Photomicrograph of positive immune staining for vimentin (40X).](image)
Figure 5: Photomicrograph of positive immune staining for LCA (40X).

Figure 6: Photomicrograph of positive immune staining for PAX 5 (40X).

Figure 7: Photomicrograph of positive immune staining for CD 3 (40X).

CK, DOG1, CD117, SMA, CD15, Alk1, CD20 and CD56 were negative. Hence a diagnosis of colonic T/HRBCL of colon was established. Patient was started on CHOP-R (Cyclophosphamide, hydroxy-daunorubicin, oncovin, prednisolone, rituximab) chemotherapy regime and advised routine to follow up.

Figure 8: Photomicrograph showing positive immune staining for CD 68 (40X).

DISCUSSION

THRLBCL is a rare morphologic variant of DLBCL with limited number of pan B (CD20 or Pax5) positive neoplastic B-cells with abundant population of the non-neoplastic CD3 positive T-cells and CD68 positive histiocytes. It causes diagnostic dilemma since it mimics the NLPHL. Morphologically diffuse architecture without rosette around atypical cells, numerous histiocytes and immunophenotypically pan B cell positivity in scant tumor cells along with CD 68 and CD3 expression in histiocytes and T lymphocytes respectively favors diagnosis of TCRLBCL than NLPHL. There is also a hypothesis that the NLPHL progress to this subtype of DLBCL. Gottesman et al, identified that the background population is distinct in both, as THRLBCL shows strong positivity of reactive T-cells in the background whereas the NLPHL shows reactive B cells. Hartmann S et al, have analysed the gene expression profiling of these entities and found BAT 3/BAG 6, HIGD1A AND FAT10/UBD expression in both. Using comparative genomic hybridization Franke S et al, concluded that TCRLBCL possibly originates from the same precursor cell of NLPHL.

Correct diagnosis is essential for management as limited field radiation therapy is administered for NLPHL in contrast to THRLBCL which is treated primarily by chemotherapy. Siricilla et al have reported a case of chemotherapy refractory THRLBCL like transformation of NLPHL which was then successfully treated with lenalidomide. Surgical debulking followed by adjuvant chemotherapy (R-CHOP) is the mainstay for localized and non-metastatic gastrointestinal disease. El Weshi et al, has reported a 5-year overall survival rate of 46% with aggressive course and poor outcome.
CONCLUSION
THRLBCL in colon is very rare and it can be diagnosed appropriately with the help of ancillary studies like immunohistochemistry and molecular diagnostics. Morphologically it consists of abundant CD 3 positive non neoplastic T cells and CD 68 positive histiocytes with limited number of CD 20 and PAX 5 positive neoplastic B cells. Identification of this entity is crucial since it very closely mimics NLPHL and treatment is entirely different. Chemotherapy (CHOP-R) is the primary treatment modality. Prognosis as reported in literature is very poor.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** Not required

REFERENCES

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon. Inter Agen Res Cancer. 2008: 309-311.
2. Ioachim HL, Ratech H. Nomenclature and classification of lymphomas. In: Ioachim Lymphnode Pathology. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2002: 315-324.
3. Ichikawa S, Watanabe Y, Saito K, Kimura J, Ichinohasama R, Harigae H. T-cell/histiocyte-rich large B-cell lymphoma of the thyroid. Exper Hematol Oncol. 2013;2(1):1.
4. Bagwan IN, Knee G, Abboudi Z, Naresh KN. Small intestinal presentation of nodular lymphocyte-predominant Hodgkin lymphoma with T cell/histiocyte-rich B cell lymphoma-like areas-with review of literature on extranodal presentation of this disease. J Hematopathol. 2010;3(1):29-34.
5. Xu J, Wu X, Reddy V. T Cell/Histiocyte-Rich large B cell lymphoma of the thymus: A diagnostic pitfall. Case Rep Hematol. 2016;2016.
6. Gocke CD. Non-Hodgkin’s lymphoma. In: Dabbs DJ. Diagnostic Immunohistochemistry. Philadelphia: Churchill Livingstone; 2002:113-34.
7. Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist. 2006;11(4):384-92.
8. Aki H, Tuzuner N, Ongoren S, Baslar Z, Soysal T, Ferhanoglu B, et al. T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. Leukemia Res. 2004;28(3):229-36.
9. Rets AV, Gottesman SR. Nodular Lymphocyte Predominant Hodgkin Lymphoma versus T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Diagnostic Challenge. Case Rep Pathol. 2014;2014.
10. Zhao FX. Nodular lymphocyte-predominant Hodgkin lymphoma or T-cell/histiocyte rich large B-cell lymphoma: the problem in “grey zone” lymphomas. Inter J Clin Exper Pathol. 2008;1(3):300.
11. Hartmann S, Döring C, Jakobus C, Rengstl B, Newrzela S, Tousseyn T, et al. Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - endpoints of a spectrum of one disease? PLoS One. 2013;8(11):78812.
12. Franke S, Wlodarska I, Maes B, Vandenberghe P, Achten R, Hagemeijer A, et al. Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma. Am J Pathol. 2002;161(5):1861-7.
13. Siricilla M, Irwin L, Ferber A. A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide. Case Rep Oncol Med. 2018;2018.
14. El Weshi A, Akhtar S, Mourad WA, Ajarim D, Abdelalim M, Khafaga Y, et al. T-cell/histiocyte-rich B-cell lymphoma: clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk lymph. 2007;48(9):1764-73.

Cite this article as: Agrawal V, Mithlesh B, Sharma S, Gopal VR. T cell/histiocyte rich large B cell lymphoma of ascending colon: a rare entity. Int Surg J 2020;7:918-21.